8BZP

JNK3 (Mitogen-activated protein kinase 10) in Complex with Compound 23 bearing a C(sp3)F2Br moiety

Summary for 8BZP

• Entry DOI: 10.2210/pdb8bzp/pdb
• Descriptor: Mitogen-activated protein kinase 10, 2-bromanyl-2,2-bis(fluoranyl)-~{N}-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)ethanamide, 1,2-ETHANEDIOL, ... (9 entities in total)
• Functional Keywords: fragment, cf2x, cf2br, halogen bond, transferase
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 2
• Total formula weight: 87234.26

Authors

Stahlecker, J.,Vaas, S.,Stehle, T.,Boeckler, F.M. (deposition date: 2022-12-15, release date: 2023-08-02, Last modification date: 2023-08-23)

Primary citation

Vaas, S.,Zimmermann, M.O.,Schollmeyer, D.,Stahlecker, J.,Engelhardt, M.U.,Rheinganz, J.,Drotleff, B.,Olfert, M.,Lammerhofer, M.,Kramer, M.,Stehle, T.,Boeckler, F.M.
Principles and Applications of CF 2 X Moieties as Unconventional Halogen Bond Donors in Medicinal Chemistry, Chemical Biology, and Drug Discovery.
J.Med.Chem., 66:10202-10225, 2023

PubMed Abstract: As an orthogonal principle to the established (hetero)aryl halides, we herein highlight the usefulness of CFX (X = Cl, Br, or I) moieties. Using tool compounds bearing CFX moieties, we study their chemical/metabolic stability and their logP/solubility, as well as the role of XB in their small molecular crystal structures. Employing QM techniques, we analyze the observed interactions, provide insights into the conformational flexibilities and preferences in the potential interaction space. For their application in molecular design, we characterize their XB donor capacities and its interaction strength dependent on geometric parameters. Implementation of CFX acetamides into our HEFLibs and biophysical evaluation (STD-NMR/ITC), followed by X-ray analysis, reveals a highly interesting binding mode for fragment in JNK3, featuring an XB of CFBr toward the P-loop, as well as chalcogen bonds. We suggest that underexplored chemical space combined with unconventional binding modes provides excellent opportunities for patentable chemotypes for therapeutic intervention.

PubMed: 37487500
DOI: 10.1021/acs.jmedchem.3c00634

Experimental method

X-RAY DIFFRACTION (1.86 Å)